Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson's Disease

28 Jan 2019

Abstract excerpt

Dopaminergic pathway is the most disrupted pathway in the pathogenesis of Parkinson’s disease. Several studies reported associations of dopaminergic genes with the occurrence of adverse events of dopaminergic treatment. However, none of these studies adopted a pathway based approach. The aim of this study was to comprehensively evaluate the influence of selected single nucleotide polymorphisms of key dopaminergic...

Source

Identifiers

PMID: 30745869
DOI: 10.3389/fphar.2019.00008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson's DiseasePMID 30745869Read ↗

Clinical and Clinical-Pharmacogenetic Models for Prediction of the Most Common Psychiatric Complications Due to Dopaminergic Treatment in Parkinson's Disease.Semantic proximity Read ↗

Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson’s diseaseSemantic proximity Read ↗

Polymorphisms of dopamine receptor genes and risk of visual hallucinations in Parkinson's patients.Semantic proximity Read ↗

Polymorphism of neurodegeneration-related genes associated with Parkinson's disease risk.Semantic proximity Read ↗

Genetic Insights into the Molecular Pathophysiology of Depression in Parkinson's Disease.Semantic proximity Read ↗

Current Data on the Genetic Background of Impulse Control Disorders in Parkinson’s DiseaseSemantic proximity Read ↗

Pharmacogenomics—a New Frontier for Individualized Treatment of Parkinson’s DiseaseSemantic proximity Read ↗

Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study.Semantic proximity Read ↗

A systematic review and integrative approach to decode the common molecular link between levodopa response and Parkinson's disease.Semantic proximity Read ↗

Candidate Genes Encoding Dopamine Receptors as Predictors of the Risk of Antipsychotic-Induced Parkinsonism and Tardive Dyskinesia in Schizophrenic PatientsSemantic proximity Read ↗

Polymorphisms in candidate genes: implications for the current treatment of Parkinson's disease.Semantic proximity Read ↗

Dopamine pathway and Parkinson’s risk variants are associated with levodopa-induced dyskinesiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.